Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aytu Biopharma stock in Canada

Own Aytu Biopharma shares in just a few minutes.

Aytu Biopharma is a drug manufacturers-specialty & generic business based in the US. Aytu Biopharma stocks (AYTU.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.54 – an increase of 5.38% over the previous week. Aytu Biopharma employs 175 staff and has a trailing 12-month revenue of around $74 million.

How to buy shares in Aytu Biopharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AYTU – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Aytu Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Aytu Biopharma's stock price?

Since the stock market crash in March caused by coronavirus, Aytu Biopharma's stock price has had significant positive movement.

Its last market close was $1.96, which is 61.58% up on its pre-crash value of $0.753 and 484.73% up on the lowest point reached during the March crash when the stocks fell as low as $0.3352.

If you had bought $1,000 worth of Aytu Biopharma stocks at the start of February 2020, those stocks would have been worth $2,630.10 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,756.68.

Aytu Biopharma stock price (NASDAQ: AYTU)

Use our graph to track the performance of AYTU stocks over time.

Aytu Biopharma shares at a glance

Information last updated 2021-11-28.
Latest market close$1.96
52-week range$1.80 - $11.76
50-day moving average $2.56
200-day moving average $4.90
Wall St. target price$17.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.07

Compare online trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Feature Table description
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks (total value up to $9,000) when you deposit and trade $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of at least $200/month. Valid until March 1, 2022.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Aytu Biopharma price performance over time

Historical closes compared with the close of $1.96 from 2021-11-29

1 week (2021-11-23) 5.38%
1 month (2021-10-28) N/A
3 months (2021-09-01) -48.83%
6 months (2021-05-28) N/A
1 year (2020-12-01) 126.59%
2 years (2019-11-29) 133.67%
3 years (2018-11-30) 94.06%
5 years (2016-11-30) 64.71%

Aytu Biopharma financials

Revenue TTM $74 million
Gross profit TTM $29.2 million
Return on assets TTM -14.54%
Return on equity TTM -80.8%
Profit margin -110.57%
Book value $4.02
Market capitalisation $55.2 million

TTM: trailing 12 months

Aytu Biopharma share dividends

We're not expecting Aytu Biopharma to pay a dividend over the next 12 months.

Have Aytu Biopharma's shares ever split?

Aytu Biopharma's shares were split on a 1:10 basis on 9 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aytu Biopharma shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Aytu Biopharma shares which in turn could have impacted Aytu Biopharma's share price.

Aytu Biopharma share price volatility

Over the last 12 months, Aytu Biopharma's shares have ranged in value from as little as $1.8 up to $11.76. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aytu Biopharma's is -0.346. This would suggest that Aytu Biopharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Aytu Biopharma has bucked the trend.

Aytu Biopharma overview

Aytu Biopharma, Inc. , a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site